Hypothesis

Age‑associated loss of chromatin accessibility at lineage‑priming enhancers is not a static epigenetic scar but a reversible bistable state maintained by reduced pioneer factor binding and increased activity of the NuRD remodeler CHD4. Transient overexpression of a pioneer factor (e.g., FOXA1) combined with pharmacological inhibition of CHD4 will reset enhancer accessibility, restore youthful transcriptional programs, and rejuvenate stem‑cell function.

Mechanistic rationale

• In young stem cells, pioneer factors such as FOXA1 bind closed nucleosomal DNA, recruit histone acetyltransferases (p300/CBP), and create accessible enhancers that drive quiescence, niche adhesion, and lineage commitment [1, 2].
• With age, these pioneer‑factor sites lose accessibility, showing increased nucleosome occupancy and histone deacetylation [3, 4]. Concurrently, the NuRD complex subunit CHD4 shows heightened activity at the same loci, compacting chromatin and blocking pioneer factor rebinding [5, 6]
• This creates a self‑reinforcing loop: low pioneer factor binding → reduced HAT recruitment → more closed chromatin → greater CHD4‑mediated compaction → further exclusion of pioneer factors.
• Because the loop depends on enzyme activities rather than irreversible DNA methylation, perturbing either side should break the cycle and allow the enhancer to revert to an open state.

Predictions

1. Accessibility reset – scATAC‑seq from aged HSCs or NSCs treated with inducible FOXA1 (4‑OHT) plus a CHD4 inhibitor (e.g., CHD4‑i) will show restored FOXA1‑motif accessibility at quiescence‑ and adhesion‑gene enhancers to levels comparable to young cells.
2. Transcriptional rejuvenation – RNA‑seq will reveal upregulation of quiescence signatures (e.g., p21, Cxcl12) and downregulation of senescence‑associated secretory phenotype (SASP) genes.
3. Functional rescue – Treated aged stem cells will exhibit improved niche retention (in vivo homing assay), enhanced migratory capacity after Rho/ROCK inhibition, and balanced lineage output in competitive transplantation.
4. Bistability test – Removing FOXA1 induction after a 48‑h pulse will maintain the open enhancer state for at least two cell divisions, whereas CHD4 inhibition alone will produce only transient accessibility that decays upon washout.
5. Falsifiability – If FOXA1 overexpression + CHD4 inhibition fails to enhance enhancer accessibility or functional readouts beyond baseline aged levels, the hypothesis is refuted.

Experimental design

• Cell models: murine aged HSCs (Lin⁻Sca1⁺cKit⁺CD150⁺CD48⁻) and NSCs (Sox2⁺GFAP⁺) isolated from 20‑month‑old mice.
• Interventions: doxycycline‑inducible FOXA1‑ERT2 construct; CHD4 inhibitor (validated dose from literature) or CRISPRi‑mediated CHD4 knock‑down; controls: vehicle, FOXA1 alone, CHD4i alone.
• Readouts (performed at 0, 24, 48, 72 h post‑induction):
  • scATAC‑seq (10x) focusing on FOXA1 motifs, quiescence, adhesion, lineage‑priming enhancers.
  • scRNA‑seq for transcriptional states.
  • Functional assays: competitive transplantation (HSCs), in vivo homing and migration (NSCs), colony‑forming unit assays.
  • ChIP‑seq for FOXA1, H3K27ac, CHD4 to confirm mechanistic changes.
• Statistical plan: n ≥ 3 biological replicates; differential accessibility tested with DESeq2 (FDR < 0.05); functional outcomes analyzed by ANOVA with post‑hoc Tukey.

Potential outcomes

• Support: Coordinated increase in FOXA1 binding, H3K27ac, and decreased CHD4 occupancy at target enhancers; sustained transcriptional and functional improvement after transient induction.
• Refute: No change in accessibility despite FOXA1/CHD4 modulation, or changes that are strictly transient and fail to affect stem‑cell behavior, indicating that age‑related enhancer loss is locked by additional mechanisms (e.g., irreversible DNA methylation or higher‑order chromatin folding).

By directly testing whether pioneer factor activity can overcome age‑dependent NuRD‑mediated compaction, this hypothesis bridges the observed accessibility erosion with a concrete, reversible molecular switch, offering a clear path toward rejuvenating aged stem cells.